These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 21528176)

  • 1. High-dose chemotherapy with bone marrow transplantation for advanced colorectal cancer.
    Codaccipisanelli G; Seminara P; Gargano L; Accordino M; Sbaffi E; Bonaiuti V; Rossetti R; Franchi F
    Int J Oncol; 1997 Jul; 11(1):25-9. PubMed ID: 21528176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
    van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
    Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer.
    Anscher MS; Peters WP; Reisenbichler H; Petros WP; Jirtle RL
    N Engl J Med; 1993 Jun; 328(22):1592-8. PubMed ID: 8487801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Basic and clinical studies on patients who have undergone autologous or allogeneic bone marrow transplantation].
    Kasai M; Imai K; Seto K; Kobayashi N; Kawamura K; Higa T; Ariyama T; Meguro J; Kukita K; Yonekawa M
    Hokkaido Igaku Zasshi; 1988 Jul; 63(4):589-96. PubMed ID: 3065193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose chemotherapy with autologous bone marrow transfusion.
    Spitzer G; Dicke KA; Verma DS; Zander A; Litam J; DiStefano A; Lanzotti V
    Exp Hematol; 1979; 7 Suppl 5():38-53. PubMed ID: 400700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer.
    Tallman MS; Rademaker AW; Jahnke L; Brown SG; Bauman A; Mangan C; Kelly C; Rubin H; Kies MS; Shaw J; Kiel K; Gordon LI; Gradishar WJ; Winter JN
    Bone Marrow Transplant; 1997 Nov; 20(9):721-9. PubMed ID: 9384473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies.
    Khalil A; Ciobanu N; Sparano JA; Gucalp R; Dutcher JP; Wiernik PH
    Bone Marrow Transplant; 1995 Jan; 15(1):93-7. PubMed ID: 7742763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
    Ager S; Mahendra P; Richards EM; Bass G; Baglin TP; Marcus RE
    Bone Marrow Transplant; 1996 Mar; 17(3):335-40. PubMed ID: 8704683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma.
    Miniero R; Brach del Prever A; Vassallo E; Nesi F; Busca A; Fagioli F; Albiani R; Picci P; Bacci G; Madon E
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S37-40. PubMed ID: 9989888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma.
    Lotz JP; Bouleuc C; André T; Touboul E; Macovei C; Hannoun L; Lefranc JP; Houry S; Uzan S; Izrael V
    Cancer; 1996 Jun; 77(12):2550-9. PubMed ID: 8640705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-haematological toxicity limiting the application of sequential high dose chemotherapy in patients with advanced breast cancer.
    Pittman KB; To LB; Bayly JL; Olweny CL; Abdi EA; Carter ML; Malycha P; Gill PG; Walsh J; Ward GG
    Bone Marrow Transplant; 1992 Dec; 10(6):535-40. PubMed ID: 1362687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High-doses chemotherapy followed by bone marrow autograft in the treatment of small cell bronchial cancer].
    Pico JL; Baume D; Ostronoff M; Beaujean F; Gouyette A; Le Chevalier T; Arriagada R; Rebattu P; Hayat M
    Bull Cancer; 1987; 74(5):587-95. PubMed ID: 2825862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies.
    Bandini G; Belardinelli A; Rosti G; Calori E; Motta MR; Rizzi S; Benini C; Tura S
    Bone Marrow Transplant; 1994 May; 13(5):577-81. PubMed ID: 8054910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of autologous bone marrow transplantation in cancer chemotherapy].
    Tajima T; Tokuda Y; Kubota M; Ohta M; Yokoyama S; Mitomi T; Nakamura Y; Watanabe K; Murakami M; Shinozuka T
    Gan To Kagaku Ryoho; 1988 Nov; 15(11):3018-24. PubMed ID: 3056274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver.
    Fisher DC; Vredenburgh JJ; Petros WP; Hussein A; Berry DA; Elkordy M; Rubin P; Gilbert CJ; Peters WP
    Bone Marrow Transplant; 1998 Jan; 21(2):117-22. PubMed ID: 9489626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma.
    Einsele H; Bamberg M; Budach W; Schmidberger H; Hess CF; Wörmann B; Meisner C; Straka C; Hebart H; Trümper L; Kröger N; Zander AR; Hegewisch-Becker S; Hossfeld DK; Schmidt H; Müller P; Schlimok G; Hertenstein B; Peest D; Metzner B; Frickhofen N; Kanz L; Bensinger WI
    Bone Marrow Transplant; 2003 Sep; 32(6):593-9. PubMed ID: 12953132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
    Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations.
    Spitzer G; Dicke KA; Verma DS; Zander A; McCredie KB
    Cancer Treat Rep; 1979 Aug; 63(8):1257-64. PubMed ID: 383292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
    Ridola V; Grill J; Doz F; Gentet JC; Frappaz D; Raquin MA; Habrand JL; Sainte-Rose C; Valteau-Couanet D; Kalifa C
    Cancer; 2007 Jul; 110(1):156-63. PubMed ID: 17541945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.